stockrow
Saturday 7 November 2026
Export TECX’s income statement to Excel — free account
Tectonic Therapeutic, Inc.
TECX Healthcare Biotechnology
- EPS
- −10.3%
- Free cash flow
- −46.7%
- Total debt
- −94.0%
Quarter to June 2026, against a year earlier
20.62
1.20
+6.18%
Follow TECX
Alert me
Tectonic Therapeutic, Inc. (TECX) P/E ratio
Tectonic Therapeutic, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ZURA Zura Bio Limited compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| EDIT Editas Medicine, Inc. compare | n/m |
| ALT Altimmune, Inc. compare | n/m |
| TECX Tectonic Therapeutic, Inc. | n/m |
| ALLO Allogene Therapeutics, Inc. compare | n/m |
| CCCC C4 Therapeutics, Inc. compare | n/m |
| BLSM BlossomHill Therapeutics, Inc. compare | n/m |
| LYEL Lyell Immunopharma, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)